Press Release
January 13, 2021

Enara Bio and Boehringer Ingelheim Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared Antigens for Cancer Immunotherapies

The Life Sciences team advised Enara Bio on its strategic collaboration and licensing agreement with Boehringer Ingelheim to research and develop novel targeted cancer immunotherapies, leveraging Enara Bio’s Dark Antigen™ discovery platform.


Enara Bio (formerly Ervaxx) is a science-led company targeting the T-cell/cancer-cell interface (the “immune synapse”) to develop new targeted cancer immunotherapies designed to treat a broad patient population. Enara Bio’s proprietary Dark Antigen Platform Technology (EDAPT™) will be used to discover and validate novel Dark Antigens in up to three tumor types in the lung and gastrointestinal cancer space.


Under the agreement, Enara Bio is eligible to receive an upfront payment, together with research/preclinical milestones and licensing fees for each tumor type that is explored. Enara Bio is also eligible to receive more than EUR 876 million in clinical, regulatory and commercial milestones, in addition to royalties on future product sales.


The Goodwin team was led by Emily Beman and Noelle Dubiansky, with invaluable assistance from Sabrina PoulosWilliam Weintraub, and Robert Carroll.


For more details, read the press release and articles in FierceBiotech, BioSpace, and The Pharma Letter.